Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.
Pemetrexed is a multitargeted antifolate approved for the second-line treatment of locally advanced or metastatic non-small cell lung cancer. The combination of pemetrexed with gemcitabine has been studied in several clinical trials showing a promising antitumor activity with a mild toxicity profile. We present the case of a patient who experienced fever, arthralgia, skin rash and high serum ferritin levels after first cycle of this chemotherapy combination, compatible with an adult onset Still's disease. This adverse event has not been previously reported.
Bosch-Barrera
Joaquim
J
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Montero
Alberto
A
López-Picazo
José María
JM
García-Foncillas
Jesús
J
Ferrer
Marta
M
Yuste
José Ramón
JR
Gil-Bazo
Ignacio
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed; D016706:Still's Disease, Adult-Onset / Q000139:chemically induced* / Q000188:drug therapy; D000093542:Gemcitabine
D005971:Glutamates; D000068437:Pemetrexed; D003841:Deoxycytidine; D006147:Guanine; D000093542:Gemcitabine